Comparison of Dynamic Contrast-Enhancement Parameters between Gadobutrol and Gadoterate Meglumine in Posttreatment Glioma: A Prospective Intraindividual Study.

Abstract

BACKGROUND AND PURPOSE:

Differences in molecular properties between one-molar and half-molar gadolinium-based contrast agents are thought to affect parameters obtained from dynamic contrast-enhanced imaging. The aim of our study was to investigate differences in dynamic contrast-enhanced parameters between one-molar nonionic gadobutrol and half-molar ionic gadoterate meglumine in patients with posttreatment glioma.

MATERIALS AND METHODS:

This prospective study enrolled 32 patients who underwent 2 20-minute dynamic contrast-enhanced examinations, one with gadobutrol and one with gadoterate meglumine. The model-free parameter of area under the signal intensity curve from 30 to 1100 seconds and the Tofts model-based pharmacokinetic parameters were calculated and compared intraindividually using paired t tests. Patients were further divided into progression (n = 12) and stable (n = 20) groups, which were compared using Student t tests.

RESULTS:

Gadobutrol and gadoterate meglumine did not show any significant differences in the area under the signal intensity curve or pharmacokinetic parameters of K trans, Ve, Vp, or Kep (all P > .05). Gadobutrol showed a significantly higher mean wash-in rate (0.83 ± 0.64 versus 0.29 ± 0.63, P = .013) and a significantly lower mean washout rate (0.001 ± 0.0001 versus 0.002 ± 0.002, P = .02) than gadoterate meglumine. Trends toward higher area under the curve, K trans, Ve, Vp, wash-in, and washout rates and lower Kep were observed in the progression group in comparison with the treatment-related-change group, regardless of the contrast agent used.

CONCLUSIONS:

Model-free and pharmacokinetic parameters did not show any significant differences between the 2 gadolinium-based contrast agents, except for a higher wash-in rate with gadobutrol and a higher washout rate with gadoterate meglumine, supporting the interchangeable use of gadolinium-based contrast agents for dynamic contrast-enhanced imaging in patients with posttreatment glioma.

• Authors: J E Park, J Y Kim, H S Kim, W H Shim
• Journal: AJNR. American journal of neuroradiology (AJNR Am J Neuroradiol) Vol. 41 Issue 11 Pg. 2041-2048 (11 2020) ISSN: 1936-959X [Electronic] United States
• PMID: 33060100 (Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
• Copyright: © 2020 by American Journal of Neuroradiology.

Chemical References

• Contrast Media
• Organometallic Compounds
• gadobutrol
• Meglumine
• gadoterate meglumine

Topics

• Adult
• Aged
• Contrast Media (pharmacokinetics)
• Female
• Glioma (diagnostic imaging)
• Humans
• Image Interpretation, Computer-Assisted (methods)
• Magnetic Resonance Imaging (methods)
• Male
• Meglumine (pharmacokinetics)
• Middle Aged
• Organometallic Compounds (pharmacokinetics)
• Prospective Studies
• Reproducibility of Results
• Young Adult